Navigation Links
Gene therapy increases survival for end-stage head and neck cancer
Date:5/28/2008

mmons Cancer Center in Dallas, are available at www.introgen.com.

Better Quality of Life

Patients treated with Advexin experienced far fewer harmful side effects such as pneumonia than those who received methotrexate. The incidence of inflammation of the mouth lining and a decrease in white blood cells, for example, both dropped to zero for those receiving Advexin.

"That certainly results in a better quality of life," Roth noted, which makes sense because p53 does not cause problems in normal cells.

Roth's lab has been developing gene therapy for cancer since 1990. "We wanted to go beyond conventional treatment, because most of those treatments were not very effective," Roth said. "Surgery and radiation are limited to the local tumor and once given, it's very hard to repeat those therapies. Chemotherapy inhibits DNA replication, but it also interferes with normal cells."

From idea to Phase I Trial at M. D. Anderson

All basic and preclinical work on the modified adenovirus was done at M. D. Anderson. The first phase I clinical trial was conducted by Gary Clayman, M.D., D.D.S., professor in M. D. Anderson's Department of head and neck surgery. Clayman also enrolled patients in the phase II and phase III clinical trials conducted by Introgen.

Roth and colleagues deleted an important region of the adenovirus' genome, preventing it from replicating. They installed a genomic segment that expresses p53. When injected into a tumor, the p53 adenovirus burrows into the cancer cell's nucleus. But instead of replicating in a typical viral manner, it expresses p53, resulting in cell death.

Clayman's phase I trial provided the first indicator that p53 expression in the tumor before treatment could be an accurate biomarker for p53 therapy. The concept was further developed retrospectively in Introgen's phase II trial, Roth said, and then it was applied prospe
'/>"/>

Contact: Scott Merville
smerville@mdanderson.org
713-792-0661
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert  

Page: 1 2 3 4

Related medicine news :

1. Vision restoration therapy shown to improve brain activity in brain injured patients
2. HIV therapy in pregnancy-data support WHO recommendations
3. Family-based treatment more effective than supportive psychotherapy in treating bulimia
4. Trial to Test Gene Therapy for Angina in Women
5. One of the Largest Post-WHI Physician Surveys Shows More Education is Needed: Patient Misinformation About Hormone Therapy Remains High
6. Aromatherapy Gift Line Sheds Humorous Light on Modern Therapy
7. Chemotherapy may be culprit for fatigue in breast cancer survivors
8. Atlanta Falcons Physical Therapy Centers Set to Launch This Fall
9. New Drug No Substitute for Standard Blood-Clot Therapy
10. Stem Cell Therapy Disappoints Against Rare Kidney Ailment
11. Nucletron Announces Management Buy-Out to More Effectively Meet the Demands of Its Customers and the Radiation Therapy Community
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Gene therapy increases survival for end-stage head and neck cancer
(Date:6/29/2015)... ... June 29, 2015 , ... Scientists from ... to build nearly complete genomes by combining high-throughput DNA sequencing with genome mapping. ... for their association with human disease, but previously difficult to detect. The study ...
(Date:6/29/2015)... ... June 29, 2015 , ... Assurex Health, a ... certain neuropsychiatric and chronic pain conditions, has announced appointments to three key leadership ... Peter Donato, Senior Vice President, Chief Financial Officer; Craig S. Lewis, Senior Vice ...
(Date:6/29/2015)... ... June 29, 2015 , ... OR Manager announced Monday the launch of an ... well as a redesigned logo and weekly eLetter. The website contains the same informational ... and easier to navigate. , In addition to a refreshed look, http://www.ormanager.com ...
(Date:6/29/2015)... ... 29, 2015 , ... Bionops Laboratories has released the first ... consumers. , The specialized eye health formulation contains a variety of ingredients to ... addition to Citicoline (Cognizin®), Biomacula provides necessary doses of Vitamin E, Glutathione, Resveratrol, ...
(Date:6/29/2015)... ... June 29, 2015 , ... FACE is proud to be one of ... reduction of the double chin and redefining of the jawline. Excess fat under ... older and heavier causing the person distress and poor self-image. , Kybella was produced ...
Breaking Medicine News(10 mins):Health News:Mount Sinai Scientists Develop New Approach for More Accurate and Comprehensive Whole Genome Assembly, Variant Discovery and Interpretation 2Health News:Mount Sinai Scientists Develop New Approach for More Accurate and Comprehensive Whole Genome Assembly, Variant Discovery and Interpretation 3Health News:Mount Sinai Scientists Develop New Approach for More Accurate and Comprehensive Whole Genome Assembly, Variant Discovery and Interpretation 4Health News:Assurex Health Names Executives to Posts as CFO, CMO and VP/Clinical Operations 2Health News:Assurex Health Names Executives to Posts as CFO, CMO and VP/Clinical Operations 3Health News:OR Manager Launches New Website 2Health News:Bionops Laboratory Releases Biomacula, the First French Product with Citicoline (Cognizin®) 2Health News:Bionops Laboratory Releases Biomacula, the First French Product with Citicoline (Cognizin®) 3Health News:FACE Detroit Skin and Wellness Clinic Introduces Newly FDA Approved Kybella for the elimination of the Double Chin. 2
... single nucleotide polymorphisms (SNPs), that are associated with a ... breast cancer do not appear to substantially improve the ... predict an individual,s risk, according to a study in ... of the National Cancer Institute . , Risk prediction ...
... Pittsburgh-led researchers could provide new insight into how ... arteriovenous malformations (AVMs)develop in humans, as reported in ... . , Led by Beth Roman, an assistant ... Arts and Sciences, the team created the first ...
... yet to show drop-off in access predicted by critics ... have not lost access to care despite federal legislation ... years, a new report finds. , Critics feared the ... make treatment more difficult, but investigators from the Duke ...
... current assessments, report says , , TUESDAY, July 8 (HealthDay ... in the ankle and the arm can help improve ... other cardiovascular problems, an international research group reports. ... is extremely easy to perform and doesn,t require expensive, ...
... blizzard of health-related,information, consumers and medical practitioners ... good from bad and keep up-to-date on ... leader in,enterprise search, recently published three case ... new search technologies to better,serve their users ...
... factor that keeps muscles from getting too big may optimize ... two myostatin inhibitors in mice with limb injuries, first to ... delivery mechanism, says Dr. Mark Hamrick, bone biologist in the ... , "Fifty to 60 percent of the injuries occurring ...
Cached Medicine News:Health News:Single-nucleotide polymorphisms do not substantially improve risk prediction for breast cancer 2Health News:Pitt-led research provides insight into development of congenital circulatory defects 2Health News:Cancer Care Unaffected by Doctor Reimbursement Changes 2Health News:Ankle-Arm Blood Pressure Test Predicts Heart Disease Risk 2Health News:Vivisimo Case Studies Detail Innovative Enterprise Search Applications by Medical Libraries, Women's Health Site 2Health News:Vivisimo Case Studies Detail Innovative Enterprise Search Applications by Medical Libraries, Women's Health Site 3Health News:Myostatin inhibitors may improve recovery of wartime limb injuries 2Health News:Myostatin inhibitors may improve recovery of wartime limb injuries 3
(Date:6/29/2015)... ZIONA, Israel , June 29, ... BVXV, TASE: BVXV) today announced positive preliminary results from ... candidate for a universal influenza vaccine. In this trial, ... of 50 to 65, followed by an administration of ... later. M-001 was found to be safe and well ...
(Date:6/29/2015)... Calif. , June 29, 2015  Isis Pharmaceuticals, ... has been added to the Russell 1000 Index, effective ... performance of the large-cap segment of the U.S. equity ... Index and includes approximately 1000 of the largest securities ... current index membership. "We are pleased to ...
(Date:6/29/2015)... Calif. , June 29, 2015  Arbor ... medical workstation lineup. The high-powered, multi-functional M2150 ... generation Intel® Haswell Core i5-4402E 1.6 ... provide significant data processing and computing performance. Integrated ... making the unit well suited for graphics-intense applications ...
Breaking Medicine Technology:BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 2BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 3ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 2ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 3Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 2Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 3
... , CHEYENNE, Wyo., Aug. 24 The ... of its Pay-for-Participation (P4P) program, a component of its innovative ... collaboration between the practitioner community and the Wyoming EqualityCare (EC) ... Wyoming Medicaid members. , , (Logo: ...
... Curemark Founder and CEO Dr. Joan Fallon delivered the ... Conference at Harvard Medical School on July 14th. , ... conclave is particularly significant, since epigenetics is the study of ... in the DNA sequence. Presenters at the session showcased many ...
Cached Medicine Technology:Wyoming Department of Health's Pay-for-Participation Program Reports Positive Clinical Outcomes 2Wyoming Department of Health's Pay-for-Participation Program Reports Positive Clinical Outcomes 3Curemark CEO Presents at Epigenomics Conference 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: